Stichting European Myeloma Network
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Employees
- -
- Market Cap
- -
European Myeloma Network (EMN) Sample Project
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 6000
- Registration Number
- NCT06237803
- Locations
- 🇨🇿
Fakutni nemocnice Ostrava, Ostrava, Czechia
🇨🇿Nemocnice Pelhrimov, Pelhřimov, Czechia
🇨🇿Všeobecná Fakultnà nemocnice v Praz, Praha, Czechia
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 200
- Registration Number
- NCT06189833
- Locations
- 🇬🇷
St Savvas Cancer Hospital, Athens, Greece
🇩🇪Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany
🇦🇹Innsbruck Medical University, Innsbruck, Austria
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 50
- Registration Number
- NCT06183489
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇮🇹Ospedale Santo Spirito Ospedale -Azienda Sanitaria Locale Di Pescara, Roma, Italy
🇮🇹A.O.U. Policlinico S. Martino - Ematologia, Genova, Italy
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 1572
- Registration Number
- NCT05243797
- Locations
- 🇧🇷
IDOR- Instituto D'or de pesquisa. Av. São Rafael, Salvador, Brazil
🇧🇷Departamento de Oncologia ClÃnica AC Camargo Cancer Center, São Paulo, Brazil
🇧🇷Hemocentro UNICAMP, Universidade Estadual de Campinas, São Paulo, Brazil
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 222
- Registration Number
- NCT05028348
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸University of California, San Francisco, Fresno, California, United States
A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe
- Conditions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 4481
- Registration Number
- NCT04937777
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Limoges, Department of Clinical Hematology and Cell Therapy, Limoges, France
🇫🇷Service de Néphrologie, Hémodialyse Et Transplantation Rénale, Hôpital Jean Bernard, Chu Poitiers, Poitiers, France
🇦🇹Allgemeines Krankenhaus Der Stadt Wien (General Hopsital), Universitätsklinik Für Innere Medizin I Klinische Abteilung Für Onkologie (Clinic of Internal Medicine I), Medizinische Universität Wien, Wien, Austria
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 35
- Registration Number
- NCT04617925
- Locations
- 🇫🇷
Centre hospitalier Universitaire de Limoges -, Limoges, France
🇩🇪University Hospital Heidelberg, Heidelberg, Germany
🇬🇷General Hospital of Athens "Alexandra", Athens, Greece
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 160
- Registration Number
- NCT04564703
- Locations
- 🇬🇷
Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens, Greece
🇫🇷CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes, France
🇮🇹Ospedale Generale Regionale-Divisione di Ematologia e Centro Trapianto Midollo Osseo, Bolzano, Italy
COVID-19 Infection and Multiple Myeloma
- Conditions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 1054
- Registration Number
- NCT04492371
- Locations
- 🇬🇧
St James's University Hospital, Leeds, United Kingdom
🇨🇿University Hospital Ostrava, Ostrava, Czechia
🇮🇹AOU Consorziale Policlinico di Bari, Bari, Italy